A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (NCT04810078)
A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the drug levels, efficacy, safety, and tolerability of subcutaneous nivolumab versus intravenous nivolumab in participants with previously treated clear cell renal cell carcinoma that is advanced or has spread. The purpose of this study's substudy is to evaluate drug level biocomparability of subcutaneous nivolumab manufactured using two different manufacturing processes.
Who can join: Review the eligibility criteria below.
Location: Local Institution — Chicago, Illinois
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (89 Sites)
Showing the first 25 of 89 sites.
- Local Institution — Chicago, Illinois
- Local Institution - 0025 — Buffalo, New York
- Local Institution - 0088 — West Reading, Pennsylvania
- Local Institution - 0095 — Capital Federal, Buenos Aires
- Local Institution - 0058 — Mar del Plata, Buenos Aires
- Local Institution - 0037 — Pergamino, Buenos Aires
- Local Institution - 0079 — Parana, Córdoba Province
- Local Institution - 0030 — Río Cuarto, Córdoba Province
- Local Institution - 0066 — Viedma, Río Negro Province
- Local Institution - 0038 — Buenos Aires,
- Local Institution - 0056 — San Juan,
- Local Institution - 0064 — Curitiba, Paraná
- Local Institution - 0107 — Ijuí, Rio Grande do Sul
- Local Institution - 0039 — Porto Alegre, Rio Grande do Sul
- Local Institution - 0071 — Barretos, São Paulo
- Local Institution - 0070 — São José do Rio Preto, São Paulo
- Local Institution - 0090 — Rio de Janeiro,
- Local Institution - 0081 — São Paulo,
- Local Institution - 0096 — São Paulo,
- Local Institution - 0084 — Temuco, Araucania
- Local Institution - 0005 — Santiago, Santiago Metropolitan
- Local Institution - 0104 — Santiago, Santiago Metropolitan
- Local Institution - 0076 — Santiago, Santiago Metropolitan
- Local Institution - 0077 — Viña del Mar, Valparaiso
- Local Institution - 0063 — Brno,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Clear Cell Renal Cell Carcinoma
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery — Fairbanks, Alaska
- Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer — Los Angeles, California
- Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors — Duarte, California
- A Phase 1/2 Trial of ADI-270 in ccRCC — Redwood City, California
- Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab — Iowa City, Iowa
- Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer — Westwood, Kansas
Explore by condition: All Clear Cell Renal Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.